Streetbeat News

Analyst Ratings

CLSD

HC Wainwright & Co. analyst Yi Chen has reiterated a Buy rating on Clearside Biomedical (NASDAQ:CLSD) and maintained a price target of $6. The reaffirmation of the Buy rating and price target suggests a positive outlook on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:48 am

ARTL

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Artelo Biosciences (NASDAQ:ARTL) and maintained a $5 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:46 am

SENS

HC Wainwright & Co. analyst Vernon Bernardino has reiterated a Buy rating on Senseonics Holdings (AMEX:SENS) with a maintained price target of $2.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:45 am

EYEN

HC Wainwright & Co. analyst Matthew Caufield has reiterated a Buy rating on Eyenovia (NASDAQ:EYEN) and maintained a $12 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:41 am

SPRO

HC Wainwright & Co. analyst Raghuram Selvaraju has reiterated a Buy rating on Spero Therapeutics (NASDAQ:SPRO) and maintained a $7 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:31 am

RPHM

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Reneo Pharmaceuticals (NASDAQ:RPHM) and maintained a $30 price target on the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:29 am

TIL

HC Wainwright & Co. analyst Mitchell Kapoor has reiterated a Buy rating on Instil Bio (NASDAQ:TIL) and maintained a $2 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:27 am

BNTX

HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on BioNTech (NASDAQ:BNTX) but has reduced the price target from $180 to $133.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:26 am

EFTR

HC Wainwright & Co. analyst Robert Burns has reiterated a Buy rating on eFFECTOR Therapeutics (NASDAQ:EFTR) and maintained a $5 price target for the company's stock.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:24 am

AZTA

Needham analyst David Saxon has reiterated a Buy rating on Azenta (NASDAQ:AZTA) and maintained a price target of $68.

Portfolio Pulse from Benzinga Newsdesk

November 14, 2023 | 11:21 am